The Experts below are selected from a list of 264 Experts worldwide ranked by ideXlab platform
Dario Conte - One of the best experts on this subject based on the ideXlab platform.
-
neuroendocrine tumors of the gastro Entero pancreatic system
World Journal of Gastroenterology, 2008Co-Authors: Sara Massironi, V Sciola, M Peracchi, C Ciafardini, Matilde Pia Spampatti, Dario ConteAbstract:Gastro-Entero-pancreatic (GEP) neuroendocrine tumors (NETs) are rare neoplasms, although their prevalence has increased substantially over the past three decades. Moreover, there has been an increased clinical recognition and characterization of these neoplasms. They show extremely variable biological behavior and clinical course. Most NETs have endocrine function and secrete peptides and neuroamines that cause distinct clinical syndromes, including carcinoid syndrome; however, many are clinically silent until late presentation with mass effects. Investigation and management should be individualized for each patient, taking into account the likely natural history of the tumor and general health of the patient. Management strategies include surgery for cure or palliation, and a variety of other cytoreductive techniques, and medical treatment including chemotherapy, and biotherapy to control symptoms due to hormone release and tumor growth, with somatostatin analogues (SSAs) and alpha-interferon. New biological agents and somatostatin-tagged radionuclides are under investigation. Advances in the therapy and development of centers of excellence which coordinate multicenter studies, are needed to improve diagnosis, treatment and therefore survival of patients with GEP NETs.
Sara Massironi - One of the best experts on this subject based on the ideXlab platform.
-
neuroendocrine tumors of the gastro Entero pancreatic system
World Journal of Gastroenterology, 2008Co-Authors: Sara Massironi, V Sciola, M Peracchi, C Ciafardini, Matilde Pia Spampatti, Dario ConteAbstract:Gastro-Entero-pancreatic (GEP) neuroendocrine tumors (NETs) are rare neoplasms, although their prevalence has increased substantially over the past three decades. Moreover, there has been an increased clinical recognition and characterization of these neoplasms. They show extremely variable biological behavior and clinical course. Most NETs have endocrine function and secrete peptides and neuroamines that cause distinct clinical syndromes, including carcinoid syndrome; however, many are clinically silent until late presentation with mass effects. Investigation and management should be individualized for each patient, taking into account the likely natural history of the tumor and general health of the patient. Management strategies include surgery for cure or palliation, and a variety of other cytoreductive techniques, and medical treatment including chemotherapy, and biotherapy to control symptoms due to hormone release and tumor growth, with somatostatin analogues (SSAs) and alpha-interferon. New biological agents and somatostatin-tagged radionuclides are under investigation. Advances in the therapy and development of centers of excellence which coordinate multicenter studies, are needed to improve diagnosis, treatment and therefore survival of patients with GEP NETs.
Yalcin Cetin - One of the best experts on this subject based on the ideXlab platform.
-
Expression of fucose residues in Entero-endocrine cells
Histochemistry and cell biology, 1998Co-Authors: A. Gebert, Yalcin CetinAbstract:The binding of the fucose-specific lectin, Ulex europaeus agglutinin (UEA-I), to Entero-endocrine cells was studied in the ileum and caecum of humans, rabbits, rats, and mice. In all species investigated, numerous cells scattered in the crypt and villus epithelia intensely bound the UEA-I lectin. These cells proved to be argyrophilic and were identified as Enterochromaffin cells and peptide tyrosine tyrosine cells by immunohistochemistry. They mostly reached the gut lumen (”open type”) by slender cellular processes. At the ultrastructural level, fucose binding sites were located in the matrix of the electron-dense secretory granules of these cells and in the glycocalyx covering their apical membrane. The results show that in various mammalian species Entero-endocrine cells of defined types express fucose-bearing glycoconjugates. The presence of fucose residues in the apical membrane of Entero-endocrine cells indicates that this membrane domain has a specialized composition of intramembranous glycoconjugates which could be involved in receptive and/or secretory functions.
Choon Ho Sung - One of the best experts on this subject based on the ideXlab platform.
-
The Effect of Thalidomide on Entero-Behcet's Disease
The Korean Journal of Pain, 2009Co-Authors: Jung Hak Kim, Voki Nam, Ho Sik Moon, Jin Ook Kim, Choon Ho SungAbstract:Behcet's disease is a chronic relapsing vasculitis characterized by recurrent aphthous oral and genital ulcers with uveitis. Multiple organs can be involved. Entero-Behcet's disease is often uncontrollable, relapsing, and can cause acute intestinal bleeding, fistula formation, or perforation. Corticosteroids, immunosuppressors, and colchicines are used to treat Entero-Behcet's disease with vary ing degree of success. Thalidomide may also be feasible. We present a 29-year-old male Entero-Behcet's patient suffering from abdominal pain, diarrhea, and back pain. He did not respond to prior treatments, but responded to thalidomide. (Korean J Pain 2009; 22: 104-106)
V Sciola - One of the best experts on this subject based on the ideXlab platform.
-
neuroendocrine tumors of the gastro Entero pancreatic system
World Journal of Gastroenterology, 2008Co-Authors: Sara Massironi, V Sciola, M Peracchi, C Ciafardini, Matilde Pia Spampatti, Dario ConteAbstract:Gastro-Entero-pancreatic (GEP) neuroendocrine tumors (NETs) are rare neoplasms, although their prevalence has increased substantially over the past three decades. Moreover, there has been an increased clinical recognition and characterization of these neoplasms. They show extremely variable biological behavior and clinical course. Most NETs have endocrine function and secrete peptides and neuroamines that cause distinct clinical syndromes, including carcinoid syndrome; however, many are clinically silent until late presentation with mass effects. Investigation and management should be individualized for each patient, taking into account the likely natural history of the tumor and general health of the patient. Management strategies include surgery for cure or palliation, and a variety of other cytoreductive techniques, and medical treatment including chemotherapy, and biotherapy to control symptoms due to hormone release and tumor growth, with somatostatin analogues (SSAs) and alpha-interferon. New biological agents and somatostatin-tagged radionuclides are under investigation. Advances in the therapy and development of centers of excellence which coordinate multicenter studies, are needed to improve diagnosis, treatment and therefore survival of patients with GEP NETs.